SEC Form 4 · accession 0001127602-19-002527
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lynne Powell
Officer — Senior VP - CCO
Period of report
Jan 18, 2019
Accepted (ET)
Jan 23, 2019 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 18, 2019 | M | 2,000 | $3.22 | A | 2,000 | D | |
| Common StockF1 | Jan 18, 2019 | S | 2,000 | $9.40 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy)F1 | $3.22 | Jan 18, 2019 | M | 2,000 | D | May 23, 2017 | May 23, 2026 | Common Stock | 2,000 | 91,427 | D |
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018.